The LKB1-AMPK pathway: metabolism and growth control in tumor suppression
By D. Shackelford, R. Shaw. Nature Reviews. Cancer, 2009
1,941 citations recorded by the source corpus.
In the past decade, studies of the human tumour suppressor LKB1 have uncovered a novel signalling pathway that links cell metabolism to growth control and cell polarity. LKB1 encodes a serine–threonine kinase that directly phosphorylates and activates AMPK, a central metabolic sensor. AMPK regulates lipid, cholesterol and glucose metabolism in specialized metabolic tissues, such as liver, muscle and adipose tissue. This function has made AMPK a key therapeutic target in patients with diabetes. The connection of AMPK with several tumour suppressors suggests that therapeutic manipulation of this pathway using established diabetes drugs warrants further investigation in patients with cancer.
Subfields: Cancer Research, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/d1ef87712b1b3570c25b4a776b491893eb0cef8b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- Ralph J. Deberardinis
- Russell G. Jones
- B. Faubert
- Eyal Gottlieb
- Raúl V. Dúran
- Antero Salminen
- Dan A. Tennant
- K. Kaarniranta
In Molecular Biology
- David M. Sabatini
- Ralph J. Deberardinis
- Russell G. Jones
- Bruce E. Kemp
- B. Faubert
- Marta Rubio‐Texeira
- G. Thomas
- P. Siegel
Citations in the corpus
- AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan (2011, background): “In addition, the LKB1– AMPK signaling is a powerful tumor suppressor pathway, and there are therapeutic implications that AMPK agonists could be potent cancer drugs [ 90 , 93].”
- Metformin, Independent of AMPK, Inhibits mTORC1 In a Rag GTPase-Dependent Manner (2010, background): “Elucidating the role of mTORC1 in response to energy depletion is critical because of the broad clinical use of the antidiabetic drug metformin (Libby et al., 2009; Shackelford and Shaw, 2009).”
- Targeting metabolic transformation for cancer therapy (2010, background): “Under conditions with a low ATP/AMP ratio AMPK is activated, leading to metabolic adaptation (increasing catabolism and decreasing anabolism) partially through the inhibition of mTO”
- AMPK is a negative regulator of the Warburg Effect and suppresses tumor growth in vivo (2012, background): “Due to its involvement in cellular stress resistance, AMPK has been linked to the regulation of tumorigenesis (Shackelford and Shaw, 2009).”
- Nutrient sensing and signaling in the yeast Saccharomyces cerevisiae (2014, background): “In humans, AMPK regulates lipid and glucose metabolism and has been implicated in metabolic disorders, such as diabetes, obesity, cardiovascular disease, and cancer (Shackelford & Shaw, 2009).”